Chemotherapy induces cancer therapy-related cardiac dysfunction in approximately 10% of patients, manifesting as potentially permanent or reversible direct or indirect effects.
This review highlights the importance of risk assessment, recognition, and prevention of cancer therapy-related cardiac dysfunction, which affects approximately 10% of patients.
Absolute Event Rate: 0% vs 0%
Cancer therapy-related cardiac dysfunction (CTRCD) is one of the most feared and undesirable side effects of chemotherapy, occurring in approximately 10% of the patients. It can be classified as direct (dose-dependent vs dose-independent) or indirect, either case being potentially permanent or reversible. Risk assessment, recognition, and prevention of CTRCD are crucial.
Perez et al. (Tue,) reported a other. Chemotherapy induces cancer therapy-related cardiac dysfunction in approximately 10% of patients, manifesting as potentially permanent or reversible direct or indirect effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: